Clinical Trials Logo

B-Chronic Lymphocytic Leukemia clinical trials

View clinical trials related to B-Chronic Lymphocytic Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT01400685 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Start date: December 2012
Phase: Phase 1
Study type: Interventional

Lenalidomide belongs to a group of drugs called immunomodulatory drugs (IMiD) that can modify or regulate the functioning of the immune system. It is an FDA approved drug for people with multiple myeloma. It is not currently approved for use in Chronic Lymphocytic Leukemia (CLL), but it does appear effective in CLL when used alone, and is being studied for use in combination with chemotherapy in this and other lymphomas and leukemias. In this research study we are hoping to learn more about the effects of lenalidomide on CLL when given in combination with bendamustine and rituximab, which is a highly effective regimen for initial therapy of CLL/SLL. The investigators will be looking for the highest dose of lenalidomide that can be given safely, without causing any serious or unmanageable side effects.

NCT ID: NCT00201721 Completed - Clinical trials for B-Chronic Lymphocytic Leukemia

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

Start date: July 2002
Phase: Phase 2
Study type: Interventional

This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients